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MS as an autoimmune disease
Multiple sclerosis (MS) typically presents as a series of relapses and remissions owing to episodic activation of the immune system. Ongoing central nervous system (CNS) inflammation leads to demyelination and ultimately axon transection. As MS continues, the early inflammatory disease transforms to more neurodegenerative secondary progressive MS (SPMS) characterized by the accumulation of neurological deficits and disabilities. Both immunogenetic and environmental factors have been implicated in determining an individual's susceptibility to developing MS. 1 The frequency of relapses and the time from diagnosis to the appearance of permanent disabilities vary widely between patients. However, poor outcomes are highly predictable for patients who experience numerous clinical attacks early after the onset of MS, have a brief time between relapses, develop motor or cerebellar deficits soon after diagnosis and experience noticeable and progressive disabilities (that is, a score of X3 as measured by the Kurtzke Expanded Disability Status Scale 2 or EDSS-see Table 1 ) in the first few years after diagnosis. 3 Similarly, the larger the portion of CNS affected (as determined by the total volume of demyelinated plaques on magnetic resonance imaging at presentation), the worse the patient's prognosis. 4 All currently approved therapies (b-IFN, glatiramer acetate and mitoxantrone) are believed to work by modulating the immune system. These treatments, directed at blunting but not eliminating destructive autoimmunity, have yielded modest therapeutic benefits for patients with less aggressive MS, offering the ability to slow or delay the accumulation of disabilities but rarely reducing or reversing preexisting disabilities. Newer, more potent agents that interfere with immune function (natalizumab, cladribine, fingolimod and alemtuzumab) are better at suppressing MS relapses. Experimental high-dose cytotoxic approaches targeting the immune system are warranted for patients with aggressive MS in whom standard therapy has been unsuccessful at halting or delaying the inevitable accumulation of disability.
Two lines of evidence provided preliminary support for a beneficial role of hematopoietic stem-cell transplant (HSCT) in treating aggressive MS. First, preclinical studies showed the ability of HSCT to diminish or alleviate autoimmune disease, including experimental allergic encephalitis (EAE)-an animal model of MS. 5 HSCT worked best in acute EAE when inflammation predominated in the CNS. HSCT did not alter the course of EAE late in the disease when chronic scarring had replaced acute inflammation as the pathological finding in the CNS. 6, 7 Second, there are well-documented long-lasting remissions of autoimmune diseases, 8, 9 including MS, 10 for patients with a concurrent autoimmune illness who have undergone a HSCT for malignancy. However, occasionally relapses have been reported. 11, 12 Together, these observations supported further investigations for the role of autologous HSCT (aHSCT) 
Disease considerations
The early aHSCT studies enrolled patients with severe disabilities. These studies defined the risks of the procedure, but provided limited efficacy data. Subsequently, as MS patients with lesser disabilities were treated, the impact of HSCT on the natural history of MS became apparent. The current body of evidence provides strong support for aHSCT in some patient populations, although further comparative studies will be required to clearly identify a benefit for aHSCT in others.
Disease characteristic: malignant MS
A small number of patients have undergone aHSCT for rare 'malignant' forms of MS that are characterized by very active inflammatory disease with high relapse rates leading to a rapid progression of disabilities from the onset. These patients had persistent disease activity despite treatment with numerous accepted procedures including IFN, steroids, plasmapheresis, i.v. immune globulin, azothiaprine and low doses of CY (Table 2) . They received a variety of intense Restricted to a wheelchair for mobility 6.5 Bilateral canes or braces are required for walking and walking is limited to about 20 m without rest 6.0 A cane is required for walking and walking is limited to about 100 m 5.0
Able to walk about 200 m but disabilities are severe enough to require special provisions to be able to work. There may be one severe disability, such as loss of bladder control, blindness in one eye, severe ataxia in all limbs or loss of sensation in one or two limbs. Alternatively, there may be several less severe disabilities that lead to an equivalent overall impairment 4.0
Walking is limited to about 500 m and there is another severe disability, such as ataxia in all limbs, dysarthria, visual field loss; the best corrected visual acuity is between 20/100-20/200 or there is markedly slow cognition 3.0
Fully ambulatory but there is a moderate disability, such as visual scotoma, best corrected visual acuity is between 20/60-20/100, mild reduction of cognition, severe nystagmus, tremor or incoordination of the hands that interferes with tasks, a detectable weakness in limbs, loss of proprioception or frequent urinary incontinence 0.0 Normal neurological function Abbreviations: EDSS ¼ Expanded Disability Status Scale; MS ¼ multiple sclerosis.
As the patient becomes more disabled, the EDSS rises. It rises by 0.5 increments between 0 (normal) and 10 (maximally disabled). The EDSS is calculated from subscores that qualitatively evaluate the patient's function along seven axes or functional systems. These include the pyramidal, cerebellar, brainstem, visual, mental, sensory, and bowel and bladder systems. conditioning regimens, including BEAM (BCNU þ etoposide þ cytarabine þ melphalan), BU or high-dose CY, all with anti-thymocyte globulin (ATG) [13] [14] [15] followed by unmanipulated hematopoietic stem-cell grafts. Patients experienced the expected infectious complications, predominantly febrile neutropenia and bacteremias, but there were no deaths reported. All but one patient were relapsefree without the need for ongoing immune suppression following aHSCT with up to 66 months of follow-up. The one patient who experienced a mild relapse improved with conventional treatment. All patients had a remarkable improvement in their functional abilities. Further evidence of disease control includes a disappearance of oligoclonal bands in the cerebro-spinal fluid, an absence of gadoliniumenhancing lesions and a reduction in the T2 lesion volume on magnetic resonance imaging following aHSCT. The dramatic resolution of inflammatory activity and the improvement in disabilities following transplantation in these refractory patients indicate a marked change in the natural history of this variant of MS and strongly support the use of aHSCT in this population.
Disease characteristic: patients with aggressive SPMS or frequent relapses
The majority of patients undergoing aHSCT have had poor prognosis MS, which manifests as frequent relapses or the early onset of the secondary progressive (SPMS) phase of the illness within 3 to 5 years of diagnosis. Studies, generally case series, that report the outcomes of aHSCT on MS patients with ongoing disease activity that is refractory to IFN and other conventional disease-modifying agents are summarized in Table 3 . There has not been a 'standard' transplant regimen. Different mobilization and conditioning regimens have been used throughout the published series. Some groups have used ex vivo graft manipulation to reduce the burden of reinfused immune cells. Most studies have used similar clinical end points, including measurements of acute (relapses) and chronic (progression) events related to ongoing MS activity. Similarly, imaging end points have measured the impact of acute (gadolinium enhancing) or chronic (T2 lesion burden, atrophy) inflammation in the CNS.
Although patients with relapsing-remitting MS were rarely enrolled in these studies, many of the SPMS patients had ongoing relapses before aHSCT. Clinical relapses were reported following aHSCT in one series, 27 but overall, there has been an absence of ongoing acute episodic inflammatory disease activity in most reports. Evidence of ongoing chronic disease activity was seen in 14-76% of cases in the different series with median follow-up between 1.5 to 3 years. Although the frequency of progression seems to be similar to what might be expected from historical controls, these data hide two key findings. First, in many of the transplant studies, between 5 and 60% of patients actually have significant and sustained (41.0 point) improvement in their disability score. Second, MS progression-free survival seems to level off with increasing length of follow-up after aHSCT, a change from the expected natural history wherein the proportion of patients who experience progressive disabilities increases with time. Further evidence for the effectiveness of aHSCT may come from a proposed conjoint retrospective long-term follow-up study of MS patients reported to the Autoimmune Diseases Working Party of EBMT and the Autoimmune Diseases Working Committee of CIBMTR registries. This study will determine whether the stability seen within the first 3 or 4 years after transplant extends to a decade and beyond. 29 Disease characteristic: patients with advanced disabilities
Patients with advanced disabilities reflected by EDSS scores 46 are reported to have less benefit from aHSCT. In a study by Burt et al., 30 8 of 12 patients with advanced disability progressed following aHSCT, whereas all 9 patients with a pre-aHSCT EDSS of p6 were stable during the follow-up period. MS progression occurred in 4 of 15 patients with a pre-aHSCT EDSS of X6.5 (26%), but only 2 of 11 patients with an EDSS o6.5 (18%) progressed as mentioned in a report by Nash et al. 31 This has not been a universal finding: Su et al. 27 report that three of nine patients with an EDSS p6.0 (33%) had MS progression, similar to the two progressions that occurred among six patients with an EDSS 46.0 (33%). Although the small number of patients makes robust conclusions difficult, it seems that better outcomes are seen for patients with less severe disabilities at the time of transplant.
Patients with advanced disabilities typically have SPMS and manifest little or no CNS inflammation. Thus, similar to the situation in EAE, aHSCT seems to be less effective once the CNS pathology changes from acute inflammation to chronic scarring. 6 Although it is tempting to suggest that aHSCT be limited to patients with mild disabilities, a significant proportion of patients with advanced disability actually remained stable or had less disabilities following aHSCT. Perhaps it is more important to distinguish patients with inflammatory pathology who would be expected to benefit from aHSCT despite a high disability score from those who are unlikely to benefit because the progression of their disabilities is due to chronic scarring of the CNS resulting in neurodegeneration. Thus, the clinical features (such as the time from diagnosis or the length of time with an EDSS 46.0) or radiological hallmarks of CNS inflammation (such as the presence of gadoliniumenhancing plaques or the recent appearance of new T2 lesions on magnetic resonance imaging) rather than the severity of the disability may be better suited to explain the heterogeneity in outcomes following aHSCT for patients with advanced disabilities 29 and aid in the selection of disabled patients who are more likely to benefit from aHSCT.
Disease characteristic: patients with early relapsing MS
Patients with relapsing-remitting MS might be expected to be most responsive to treatments directed at repairing the immune system. Burt et al. 16 have treated 21 relapsingremitting MS patients who had ongoing relapses during treatment with b-IFN. The patients experienced little acute Table 3 Summary of published trials of autologous peripheral blood SCT for the treatment of aggressive MS 
In the absence of a parallel cohort of patients with which to compare the outcomes, the most convincing evidence to determine the impact of aHSCT is the continued MS activity free state during an extended post-transplant follow-up period. It is easier to detect a variation from the natural history when MS is more aggressive. When the MS is characterized by marked CNS inflammation and the rapid appearance of disabilities, follow-up periods in the order of 3-5 years are sufficient. 34 Overall, the benefit from the use of high-intensity conditioning regimens followed by aHSCT in malignant or 'poor prognosis' MS is unambiguous, although the role for aHSCT in less aggressive MS is still controversial, in part because of the limited long-term follow-up.
Transplant considerations
The varied patient selection criteria and follow-up reporting make strict comparisons of outcomes between the different studies challenging; however, important inferences can be made from the current body of work about the role of certain transplant parameters in the outcome of aHSCT for MS.
Stem-cell mobilization: flares with cytokines
Cytokine mobilization of hematopoietic stem cells (HSCs) has been associated with autoimmune disease flares. 35 One patient with advanced MS, who was administered granulocyte colony-stimulating factor for stem-cell mobilization, developed a fatal cervical spinal cord lesion. 36 Several other patients developed a flare in their MS when HSCs were mobilized with G-CSF alone. 24, 27, 30, 31, 37 This may be linked to enhanced adhesion to the CNS extracellular matrix by autoreactive lymphocytes. 38 The addition of CY or steroids to the mobilization regimen seems to avert the risk of cytokine-induced flares of MS. The addition of chemotherapy to the mobilization regimen may provide additional benefits by controlling the MS better than cytokine mobilization alone. Fatalities have not been reported for the use of combined chemotherapy and cytokine HSC mobilization for patients with MS, although this has been seen for other autoimmune diseases. 39 
Stem-cell mobilization: failed mobilization
Mobilization failures occur infrequently with either cytokine or combined cytokine and chemotherapy mobilization; however, there is a trend towards better stem-cell yields with the combined mobilization regimen. 39 In many cases, adequate stem cells were obtained following a second attempt at collection. The role of newer agents for mobilization failures is uncertain. Natalizumab, a humanized anti-VLA4 MoAb, suppresses CNS inflammation and can induce a rapid and prolonged increase in the number of circulating HSCs. 40, 41 The role of plerixafor 42 has not been reported for the mobilization of stem cells in patients with autoimmune diseases.
Stem-cell transplant: role of the graft
Initially, ablation of the immune system was performed using traditional myeloablative transplant conditioning regimens. Typically, aHSCT was performed to rescue the patient from marrow aplasia induced by the conditioning regimen. Some investigators have used chemotherapy regimens, such as CY with ATG, that are non-myeloablative. The need for aHSCT in this situation is unclear. Nine patients with relapsing-remitting MS were treated with 200 mg per kg CY without stem-cell support. Hematopoietic recovery occurred between 10 and 17 days later. Although there was a reduction in MS activity, this tended to be shortlived. 33 It is unclear whether the poor outcomes are because of the lower dose intensity or the lack of a stem-cell graft.
Following allo-SCT BM-derived cells have been found to contribute not only to the supporting cells in the CNS 43 but, in some cases, to integrate into the neural network. 44 A patient treated with a sex-mismatched allogeneic HSCT for chronic myelogenous leukemia who also had MS died of transplant-related complication 20 weeks after the procedure. While only a small fraction of the leukocytes infiltrating the brain parenchyma were donor derived, 45 marrow-derived cells could potentially have effects in the CNS beyond hematopoietic reconstitution. So far, infusion of autologous HSCs without conditioning regimens have not shown convincing evidence of modulating immunologically mediated disease activity or of providing reparative activity in MS 46 or other autoimmune diseases. 47 
Stem-cell transplant: role of graft manipulation
Autoimmunity can be adoptively transferred after HSCT. 48 Graft manipulation has been used to remove contaminating immune cells from the autologous hematopoietic stem-cell graft to prevent their reintroduction after aHSCT. Positive immunomagnetic selection using anti-CD34 monoclonal antibodies and a stem-cell selection machine, namely the Ceprate (Cellpro, Bothell, WA, USA), 19 Insufficient data exist to allow conclusions to be made about the importance of immune-cell depletion in minimizing MS progression following aHSCT. There was no demonstrable difference in MS outcomes in the two studies 19, 27 that compared a small non-randomized cohort of patients who received CD34 selected grafts with a cohort that received unmanipulated grafts. Both groups of patients received a BEAM or BEAM-like conditioning regimen. Appropriate studies to detect the impact of ex vivo stem-cell purification will require both highly efficient immune-cell depletion and the use of a high-intensity conditioning regimen that results in complete immune ablation. In the absence of both these conditions, the potential homeostatic expansion of residual autoreactive lymphocytes in the patient or in the graft would obscure any benefit that might be conferred by the graft manipulation.
Stem-cell transplant: choice of conditioning regimen
An array of transplant conditioning regimens has been used, but BEAM chemotherapy with or without ATG has been the most widely used. Prospective trials comparing different transplant regimens have not been performed and it is difficult to ascribe the differences in outcomes between cohort studies to the effects of the conditioning regimen, given the differences in patient selection and other variables. Hamerschlak et al. 21 retrospectively compared sequential cohorts of patients who underwent transplantation for MS in Brazil and found that patients receiving BEAM and horse ATG had a higher regimen-related morbidity and mortality than patients who received CY and rabbit ATG. Similarly, acute regimen-related deaths reported to the EBMT occurred in patients who had received BU or BEAM regimens. 29 However, the importance of regimen intensity in procedural mortality can be reduced as experience in performing aHSCT for autoimmune diseases grows. 52 Despite the number of different chemotherapy-based conditioning regimens that have been used, regimens can be allocated to two groups on the basis of their relative intensity: high-intensity conditioning regimens that trade toxicity for the potential of better long-term control of the MS and low-intensity conditioning regimens with reduced regimen-related toxicity but perhaps inferior disease control. These different strategies may confer benefit to different populations of MS patients. The results from ongoing clinical trials could address this issue. A randomized trial comparing aHSCT after treatment with CY and ATG with standard licensed therapies in early inflammatory MS will test the low-intensity approach. The remaining three trials (Autologous Stem Cell Transplantation International Multiple Sclerosis Trial, High-Dose Immunosuppression and Autologous Stem Cell Transplantation for Poor Prognosis Multiple Sclerosis Trial and Canadian trial of autologous stem cell transplantation for poor prognosis Multiple Sclerosis) have similar patient selection criteria and disease evaluation assessment, but they use different aHSCT regimens. Ultimately, a comparison of MS outcomes between these trials will provide clues to the importance of CD34 graft selection, the conditioning chemotherapy and the use of ATG (Table 4) .
Although there is a spectrum of MS outcomes seen after aHSCT and chemotherapy-based conditioning regimens, TBI-based conditioning regimens have had uniformly poor outcomes. The rates of MS progression are strikingly high and the rates of improvement of MS disabilities are low in studies in which TBI has been used (Table 5 ). This emphasizes the need to be cognizant in balancing the neurotoxic effects of the conditioning regimen when selecting agents for immune ablation. Table 4 Summary of ongoing trials of aHSCT for the treatment of aggressive MS The four ongoing trials use strategies that differ in the intensity of the transplant preparative regimen and the use of graft manipulation. Comparison of the outcomes between these trials will provide important information for the development of a randomized phase III clinical trial of aHSCT in MS.
Transplant-related complications
The frequency and severity of toxicities are generally typical of patients undergoing aHSCT for other indications; however, certain complications have commonly developed in patients with MS that are unusual in other patient populations. This may be because of neurological disabilities, such as limitations in mobility or urinary dysfunction, or transplant variables, such as the frequent use of anti-lymphocyte Ab preparations.
Acute regimen-related toxicity
Infectious complications are by and large restricted to the peritransplant period. There is an increased incidence of urinary tract infections in some series, which is likely a reflection of the frequent use of indwelling catheter for the bladder dysfunction caused by the MS. 21, 31 Herpes virus infections are more common after aHSCT for MS. CMV reactivation was seen in 8 of 178 patients in the EBMT registry 29 and a fatal case of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder was seen in a series of 26 patients. 56 These are undoubtedly the result of intense immune suppression induced by the use of ATG in the conditioning regimens.
Engraftment syndrome
An engraftment syndrome consisting of transient fever and a rash may occur following aHSCT. Other associated symptoms include fatigue, pruritis, pulmonary symptoms and eosinophilia. A short course of steroids is adequate to treat patients with more severe symptoms, but often the course is self-limited. Whereas engraftment syndrome has occurred in up to two-third of patients in some series, 31, 57 only two cases of engraftment syndrome occurred in 178 patients who underwent aHSCT for MS reported to the EBMT registry. 29 
Non-MS secondary immune events
Recipients of aHSCT for autoimmune diseases are at risk for developing secondary non-MS-related immune events. Of 155 patients undergoing transplantation for an autoimmune disease, 6 were reported to develop different secondary autoimmune illnesses from 2 to 30 months postaHSCT. 58 Immune thrombocytopenic purpura has been reported by a number of investigators to occur after aHSCT for MS, developing anywhere from 2 to 54 months after aHSCT 16, 31 (H Atkins, personal observation). Similarly, autoimmune thyroiditis leading to long-term hypothyroidism 19, 49 has been documented in recipients of aHSCT for MS and two patients have been reported to develop an acquired FVIII inhibitor. 29 The use of ATG and particularly the use of alemtuzumab in the conditioning regimen are the risk factors for this complication.
TRM
Although uncommon, both early and late transplantrelated deaths have been reported for patients with MS. Early post-transplant fatalities were caused by severe organ damage and infectious complications. Late deaths have been reported from pneumococcal sepsis, acquired Factor VIII inhibitor 29 and progressive myelodysplasia. 49 The overall TRM has been o5%.
52
Although the specter of TRM remains a concern, it must be noted that there is a significant MS-related mortality associated with the aggressive MS experienced by patients selected for aHSCT. For example, two patients died of Table 5 Summary of autologous stem cell transplant studies using TBI containing conditioning regimens for the treatment of MS Gy of TBI before aHSCT experienced the most morbidity and had the least benefits from the treatment. Many patients continue to show ongoing progression of neurological disabilities following aHSCT with TBI containing conditioning regimens. a MS disabilities were considered worse if the last post-aHSCT EDSS increased from the pre-aHSCT EDSS by a score of 1 point if the baseline EDSS was o5.5 or an increase in the EDSS score of 0.5 points if the baseline EDSS was X5.5. b MS disabilities were considered stable if the change between the last post-aHSCT EDSS and the pre-aHSCT EDSS did not worsen or improve. c MS disabilities were considered better if the last post-aHSCT EDSS decreased from the pre-aHSCT EDSS by a score of 1 point if the baseline EDSS was o5.5 or an increase in the EDSS score of 0.5 points if the baseline EDSS was X5.5.
unresponsive advanced MS but there were no regimenrelated fatalities among 21 patients in the series by Burt et al. 30 Similarly, the EBMT reported nine deaths (seven early and two late) related to the transplant procedure among 169 patients, whereas six patients died from progressive MS over the follow-up period. 29 There is a significant mortality associated with advancing disabilities in patients with aggressive MS that is on par with the treatment-related mortality for aHSCT.
As experience with the use of aHSCT for MS has grown, there has been a reduction in procedural toxicities. The EBMT registry reported seven regimen-related deaths among 107 MS patients transplanted before 2000, but no deaths among 62 patients transplanted since then. 29 Similarly, lower regimen-related mortality is observed in centers with a high volume of aHSCT for autoimmune diseases. 52 Many of the more recent series have not seen fatalities (Table 3 ). There seems to be a 'learning' curve for procedural toxicities and regimen-related mortality, which has decreased as experience with the use of aHSCT for MS has grown.
The future
Graft vs autoimmunity-allogeneic transplantation Investigators have debated the role of allo-SCT for the treatment of MS since 2005. Caution against the use of allogeneic transplantation include the higher regimenrelated mortality, the potential for alloreactivity at the site of CNS inflammation and the use of calcineurin inhibitors that could further damage the CNS through leukoencephalopathy or microangiopathy. 59 Preclinical investigations suggest that allo-SCT may control autoimmunity by altering the recipient's immunogenetic susceptibility-EAE activity was prevented by donor grafts with genetic resistance to EAE 60À and by the induction of a graft-vsautoimmunity activity. 61 The generation of strong alloreactivity through DLI prevented the induction of EAE in recipient rodents, suggesting an allogeneic immunemediated graft-vs-autoimmunity effect.
Clinical neurological worsening and increased magnetic resonance imaging brain lesion load occurred in an allogeneic HSCT recipients with CML and coincident MS with 100% donor chimerism who developed GVHD. 45 Could GVHD affect the CNS of patients with MS who have had previous damage to the CNS? The potentially beneficial or detrimental aspects of the allograft phenomenon must be understood before clinical trials of allogeneic transplantation are initiated. Towards this end, a registry started by Dr R Nash could provide additional insights by examining the changes in MS activity of patients with MS who have undergone allogeneic transplantation for another illness.
Mesenchymal stromal cell transplants
Mesenchymal stromal cells (MSCs) have unique regenerative and immunosuppressive properties. They have already been tested as an immune-modulating agent for the treatment of severe GVHD, successfully salvaging patients with steroid-refractory GVHD with little toxicity. 62 MSCs control EAE and promote CNS regeneration in preclinical experimentation. [63] [64] [65] Preliminary human applications using intrathecal and/or i.v. MSC have begun. 66, 67 Besides addressing issues of dosing and route of MSC administration, the first proof-of-principle clinical studies will need to address whether MSCs are selective immune-modulating agents-reducing autoreactivity without suppressing protective immunity, and whether autologous MSCs harbor functional defects that render them less effective than allogeneic MSC derived from normal.
Conclusions
Unlike treatment with immunosuppressive agents, aHSCT is a fundamentally different approach to inducing longterm control of MS autoimmunity. It is not dependent on ongoing chronic immune suppression or persistent lymphopenia. Importantly, after transient immune ablation, the immune system reconstitutes and MS is controlled in the presence of a functional and clonally diverse immune system. Over 500 patients with aggressive forms of MS have undergone aHSCT in the last 15 years. Although many of these transplants have been performed in the context of phase I/II clinical trials, others have been reported to international registries. The analysis of the aggregate data has delineated important patient-and transplant-related factors. aHSCT has a 'penicillin-like' effectiveness in rare malignant forms of MS. Longstanding progressive resolution of disabilities has been seen in a substantial number of patients with aggressive forms of SPMS following aHSCT-a unique outcome that differs from currently licensed treatments.
However, aHSCT for MS is still controversial. It has not entered widespread clinical use because of its perceived high mortality, high cost, competition from new pharmaceutical agents and perceived modest long-term freedom from ongoing events. Published cohort and registry studies are dispelling concerns about the toxicity of aHSCT. The hospital costs of aHSCT for MS were determined to be $59 500 CDN through a case-costing exercise at the Ottawa Hospital. In comparison, the annual retail pharmacy price of IFN-b is between $19 378 and $28 886 CDN, while Natalizumab costs about $34 000 CDN annually at retail Ontario pharmacies (Hamilton C, personal communication). However, it remains difficult to draw conclusions about the cost-effectiveness of aHSCT for MS from economic modeling because of the imprecise assumptions about aHSCT outcomes. 68 The clinical heterogeneity of MS patients, the evolving landscape of standard therapy with emerging novel drugs and the predetermined beliefs about aHSCT in the minds of many patients and physicians are serious practical barriers to randomized trials of aHSCT in MS. But clearly, a direct comparison of aHSCT with conventional treatments in multicenter randomized trials and the publication of 5-10-year long-term follow-up data from cohort studies and international registries are a necessary next step in further defining the role of aHSCT in the management of MS.
